AIM Medical Oncology Program

This program was launched April 1, 2017, to support our members' cancer care needs, while reducing the costs of managing one of the most expensive and common diseases a member may face.

The Medical Oncology Program offers support tools for cancer treatment regimens and online access for:

• Oncologists (specializing in cancer prevention, diagnosis and treatment)
• Urologists (specializing in diseases of the urinary tract and male reproductive system), and
• Hematologists (specializing in diseases of the blood)

The program includes Cancer Treatment Pathways based on medical evidence and best practices developed with leading cancer experts. Pathways offer support in finding highly effective therapies that may be more affordable for members.

Pathway treatments are widely accepted as vital to managing oncology quality and costs. More specific than guidelines, Pathway treatments are selected based on clinical effectiveness, favorable toxicity profiles and cost. Cancer Treatment Pathways are based on a detailed review of effectiveness, harmfulness, and cost informed by a clinical library and include evidence drawn from:

• Expert consensus statements and guidelines from professional organizations, including:
  • American Society of Clinical Oncology (ASCO)
  • American Society of Hematology (ASH)
  • National Comprehensive Cancer Network (NCCN)

• Federal government agencies, including:
  • Food and Drug Administration (FDA)
  • National Cancer Institute (NCI)

See Guidelines for Site of Care (Place of Service for Medical Infusions Policy)